Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia

BMC Women's Health

Volumn 7, Issue , 2007, Pages

  Meadows, Eric S ^a   Klein, Robert ^b   Rousculp, Matthew D ^a,d   Smolen, Lee ^b   Ohsfeldt, Robert L ^c   Johnston, Joseph A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Medical Decision Modeling Inc   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; RALOXIFENE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BREAST BIOPSY; BREAST CANCER; CONSERVATIVE TREATMENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; OSTEOPENIA; POSTMENOPAUSE; PROPHYLAXIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCORING SYSTEM; SIMULATION; SOCIAL ASPECT; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; ECONOMICS; FRACTURE; METABOLIC BONE DISEASE; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; RISK; STATISTICAL MODEL; THROMBOEMBOLISM;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RALOXIFENE; RISK; THROMBOEMBOLISM;

EID: 34248583359     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-7-6     Document Type: Article

References (61)

1. World Health Organization (WHO Study Group) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study Group World Health Organ Tech Rep Ser 1994 843 1-129 7941614
2. Looker AC Orwoll ES Johnston CC Jr Lindsay RL Wahner HW Dunn WL Calvo MS Harris TB Heyse SP Prevalence of low femoral bone density in older U.S. adults from NHANES III J Bone Miner Res 1997 12 1761-1768 10.1359/ jbmr.1997.12.11.1761 9383679
3. Siris ES Chen YT Abbott TA Barrett-Connor E Miller PD Wehren LE Berger ML Bone mineral density thresholds for pharmacological intervention to prevent fractures Arch Intern Med 2004 164 1108-1112 10.1001/ archinte.164.10.1108 15159268
4. Pasco JA Seeman E Henry MJ Merriman EN Nicholson GC Kotowicz MA The population burden of fractures originates in women with osteopenia, not osteoporosis Osteoporos Int 2006 17 1404-1409 10.1007/s00198-006-0135-9 16699736
5. Schuit SC van der KM Weel AE de Laet CE Burger H Seeman E Hofman A Uitterlinden AG van Leeuwen JP Pols HA Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study Bone 2004 34 195-202 10.1016/j.bone.2003.10.001 14751578
6. Stone KL Seeley DG Lui LY Cauley JA Ensrud K Browner WS Nevitt MC Cummings SR Osteoporotic Fractures Research Group BMD at multiple sites and risk of fracture of multiple types: Long-term results from the Study of Osteoporotic Fractures J Bone Miner Res 2003 18 1947-1954 10.1359/ jbmr.2003.18.11.1947 14606506
7. Hodgson SF Watts NB Bilezikian JP Clarke BL Gray TK Harris DW Johnston CC Jr Kleerekoper M Lindsay R Luckey MM McClung MR Nankin HR Petak SM Recker RR Anderson RJ Bergman DA Bloomgarden ZT Dickey RA Palumbo PJ Peters AL Rettinger HI Rodbard HW Rubenstein HA AACE Osteoporosis TF American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. [erratum appears in Endocr Pract. 2004 Jan-Feb;10(1):90] Endocr Pract 2003 9 544-564 14715483
8. National Osteoporosis Foundation Physician's guide to prevention and treatment of osteoporosis Washington, DC: NOF 2003
9. North American Menopause Society Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society Menopause 2002 9 84-101 11875327
10. Russell RG Bisphosphonates: From bench to bedside Ann NY Acad Sci 2006 1068 367-401 10.1196/annals.1346.041 16831938
11. Draper MW The role of selective estrogen receptor modulators (SERMs) in postmenopausal health Ann NY Acad Sci 2003 997 373-377 10.1196/ annals.1290.040 14644844
12. Cummings SR Eckert S Krueger KA Grady D Powles TJ Cauley JA Norton L Nickelsen T Bjarnason NH Morrow M Lippman ME Black D Glusman JE Costa A Jordan VC The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. [erratum appears in JAMA 1999 Dec 8;282(22):2124] JAMA 1999 281 2189-2197 10.1001/jama.281.23.2189 10376571
13. Ettinger B Black DM Mitlak BH Knickerbocker RK Nickelsen T Genant HK Christiansen C Delmas PD Zanchetta JR Stakkestad J Gluer CC Krueger K Cohen FJ Eckert S Ensrud K Avioli LV Lips P Cummings SR Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial JAMA 1999 282 637-645 10.1001/jama.282.7.637 10517716
14. Vogel V Costantino J Wickerham D Cronin W Cecchini R Atkins J Bevers T Fehrenbacher L Pajon E Jr Wade J III Robidoux A Margolese R James J Lippman SM Runowicz C Ganz PA Reis SE McCaskill-Stevens W Ford LG Jordan VC Wolmark N for the National Surgical Adjuvant Breast and Bowel Project (NSABP) Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial JAMA 2006 295 2727-2741 10.1001/jama.295.23.joc60074 16754727
15. Grady D Ettinger B Moscarelli E Plouffe L Jr Sarkar S Ciaccia A Cummings S for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators Safety and Adverse Effects Associated with Raloxifene: Multiple Outcomes of Raloxifene Evaluation Obstet Gynecol 2004 104 837-844 15458908
16. Martino S Disch D Dowsett SA keech CA Mershon J Safety assessment of raloxifene over eight years in a clinical trial setting Curr Med Res Opin 2005 21 1441-1452 10.1185/030079905X61839 16197663
17. Schousboe JT Nyman JA Kane RL Ensrud KE Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women Ann Intern Med 2005 142 734-741 15867405
18. Vital Statistics of the United States: Mortality http://www.cdc.gov/nchs/ data/dvs/mortfinal2002_workipt1.pdf
19. National Osteoporosis Foundation Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis Osteoporos Int 1998 8 S1-S80 10.1007/s001980050040
20. Melton LJ III Lane AW Cooper C Eastell R O'Fallon WM Riggs BL Prevalence and incidence of vertebral deformities Osteoporos Int 1993 3 113-119 10.1007/BF01623271 8481586
21. Stevenson M Lloyd Jones M De Nigris E Brewer N Davis S Oakley J A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis Health Technol Assess 2005 9 15929857
22. Kanis JA Oden A Johnell O De Laet C Jonsson B Oglesby AK The components of excess mortality after hip fracture Bone 2003 32 468-473 10.1016/ S8756-3282(03)00061-9 12753862
23. Kanis JA Johnell O Black DM Downs RW Jr Sarkar S Fuerst T Secrest RJ Pavo I Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial Bone 2003 33 293-300 10.1016/S8756-3282(03)00200-X 13678769
24. Quandt SA Thompson DE Schneider DL Nevitt MC Black DM Fracture Intervention Trial Research Group Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: The Fracture Intervention Trial Mayo Clin Proc 2005 80 349
25. Cummings SR Black DM Thompson DE Applegate WB Barrett-Connor E Musliner TA Palermo L Prineas R Rubin SM Scott JC Vogt T Wallace R Yates AJ LaCroix AZ Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results fromthe Fracture Intervention Trial JAMA 1998 280 2077-2082 10.1001/jama.280.24.2077 9875874
26. Mikhail N Cope D Alendronate and vertebral fracture risk.[comment, see author reply] Mayo Clin Proc 2005 80 1236 16178507
27. Seeman E Alendronate and vertebral fracture risk.[comment, see author reply] Mayo Clin Proc 2005 80 1236 16178508
28. SEER 13 Registries for 2000-2002. Probability of Developing Cancer Breast Cancer by Race http://canques.seer.cancer.gov
29. National Center for Chronic Disease Prevention and Health Promotion. National Breast and Cervical Cancer Early Detection Program. Breast Cancer Stage at Time of Diagnosis http://www.cdc.gov/cancer/nbccedp/ bccpdfs/national_report.pdf
30. Cauley J Norton L Lippman ME Eckert S Krueger KA Purdie DW Farrerons J Karasik A Mellstrom D Ng KW Stepan JJ Powles TJ Morrow M Costa A Silfen SL Walls EL Schmitt H Muchmore DB Jordan VC Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-year Results from the MORE Trial Breast Cancer Res Treat 2001 65 125-134 10.1023/A:1006478317173 11261828
31. Silverstein MD Heit JA Mohr DN Petterson TM O'Fallon WM Melton LJ III Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study Arch Intern Med 1998 158 585-593 10.1001/archinte.158.6.585 9521222
32. Cushman M Tsai AW White RH Heckbert SR Rosamond WD Enright P Folsom AR Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology Am J Med 2004 117 19-25 10.1016/j.amjmed.2004.01.018 15210384
33. Heit JA Mohr DN Silverstein MD Petterson TM O'Fallon WM Melton LJ III Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study Arch Intern Med 2000 160 761-768 10.1001/archinte.160.6.761 10737275
34. Drug average wholesale price http://www.analysource.com
35. de Lissovoy G Yusen RD Spiro TE Krupski WC Champion AH Sorensen SV Cost for inpatient care of venous thrombosis: A trial of enoxaparin vs standard heparin Arch Intern Med 2000 160 3160-3165 10.1001/ archinte.160.20.3160 11074747
36. Gabriel SE Tosteson AN Leibson CL Crowson CS Pond GR Hammond CS Melton LJ III Direct medical costs attributable to osteoporotic fractures Osteoporos Int 2002 13 323-330 10.1007/s001980200033 12035765
37. Knight KK Wong J Hauch O Wygant G Aguilar D Ofman JJ Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients Value Health 2005 8 191-200 10.1111/j.1524-4733.2005.04026.x 15877591
38. Legorreta AP Brooks RJ Leibowitz AN Solin LJ Cost of breast cancer treatment. A 4-year longitudinal study Arch Intern Med 1996 156 2197-2201 10.1001/archinte.156.19.2197 8885818
39. Leibson CL Tosteson AN Gabriel SE Ransom JE Melton LJ Mortality, disability, and nursing home use for persons with and without hip fracture: A population-based study J Am Geriatr Soc 2002 50 1644-1650 10.1046/j.1532-5415.2002.50455.x 12366617
40. Fleurence RL Iglesias CP Torgerson DJ Economic evaluations of interventions for the prevention and treatment of osteoporosis: A structured review of the literature Osteoporos Int 2006 17 29-40 10.1007/ s00198-005-1943-z 15981019
41. Armstrong K Chen TM Albert D Randall TC Schwartz JS Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk Obstet Gynecol 2001 98 996-1003 10.1016/ S0029-7844(01)01624-6 11755544
42. Col NF Pauker SG Goldberg RJ Eckman MH Orr RK Ross EM Wong JB Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women Arch Intern Med 1999 159 1458-1466 10.1001/archinte.159.13.1458 10399897
43. Goeree R Blackhouse G Adachi J Cost-effectiveness of alternative treatments for women with osteoporosis in Canada Curr Med Res Opin 2006 22 1425-1436 10.1185/030079906X115568 16834841
44. Kanis JA Borgstrom F Johnell O Oden A Sykes D Jonsson B Cost-effectiveness of raloxifene in the UK: An economic evaluation based on the MORE study Osteoporos Int 2005 16 15-25 10.1007/s00198-004-1688-0 15672210
45. Mobley LR Hoerger TJ Wittenborn JS Galuska DA Rao JK Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate Med Decis Making 2006 26 194-206 10.1177/0272989X06286478 16525173
46. Gail MH Brinton LA Byar DP Corle DK Green SB Schairer C Mulvihill JJ Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 1989 81 1879-1886 10.1093/jnci/81.24.1879 2593165
47. Mullins CD Ohsfeldt RL Modeling the annual costs of postmenopausal prevention therapy: Raloxifene, alendronate, or estrogen-progestin therapy J Manag Care Pharm 2003 9 150-158 14613344
48. Rossouw JE Anderson GL Prentice RL LaCroix AZ Kooperberg C Stefanick ML Jackson RD Beresford SA Howard BV Johnson KC Kotchen JM Ockene J Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial JAMA 2002 288 321-333 10.1001/jama.288.3.321 12117397
49. Rockhill B Spiegelman D Byrne C Hunter DJ Colditz GA Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention J Natl Cancer Inst 2001 93 358-366 10.1093/jnci/93.5.358 11238697
50. Barrett-Connor E Mosca L Collins P Geiger MJ Grady D Kornitzer M McNabb MA Wenger NK Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 125-137 10.1056/NEJMoa062462 16837676
51. Woo SB Hellstein JW Kalmar JR Systematic review: Bisphosphonates and osteonecrosis of the jaws Ann Intern Med 2006 144 753-761 16702591
52. Fisher B Costantino JP Wickerham DL Redmond CK Kavanah M Cronin WM Vogel V Robidoux A Dimitrov N Atkins J Daly M Wieand S Tan-Chiu E Ford L Wolmark N Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 1998 90 1371-1388 10.1093/jnci/90.18.1371 9747868
53. Cykert S Phifer N Hansen C Tamoxifen for breast cancer prevention: A framework for clinical decisions Obstet Gynecol 2004 104 433-442 15339751
54. Kanis JA Black D Cooper C Dargent P Dawson-Hughes B De Laet C Delmas P Eisman J Johnell O Jonsson B Melton L Oden A Papapoulos S Pols H Rizzoli R Silman A Tenenhouse A International Osteoporosis Foundation, National Osteoporosis Foundation A new approach to the development of assessment guidelines for osteoporosis Osteoporos Int 2002 13 527-536 10.1007/ s001980200069 12111012
55. Macran S Weatherly H Kind P Measuring population health: A comparison of three generic health status measures Med Care 2003 41 218-231 10.1097/ 00005650-200302000-00004 12555050
56. Kanis JA Johnell O Oden A Borgstrom F Zethraeus N De Laet C Jonsson B The risk and burden of vertebral fractures in Sweden Osteoporos Int 2004 15 20-26 10.1007/s00198-003-1463-7 14593450
57. Oleksik A Lips P Dawson A Minshall ME Shen W Cooper C Kanis J Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures J Bone Miner Res 2000 15 1384-1392 10.1359/jbmr.2000.15.7.1384 10893688
58. Brown RE Hutton J Burrell A Cost effectiveness of treatment options in advanced breast cancer in the UK Pharmacoeconomics 2001 19 1091-1102 10.2165/00019053-200119110-00003 11735676
59. Brown RE Hutton J Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients Anticancer Drugs 1998 9 899-907 10.1097/00001813-199811000-00009 9890701
60. Launois R Reboul-Marty J Henry B Bonneterre J A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine Pharmacoeconomics 1996 10 504-521 10169397
61. Norum J Olsen JA Wist EA Lumpectomy or mastectomy? Is breast conserving surgery too expensive? Breast Cancer Res Treat 1997 45 7-14 10.1023/ A:1005804101106 9285112